Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Fluvastatin (XU-62320; Fluindostatin; Lescol XL; XU-62-320; Canef; Lipaxan; Vastin), an approved drug belonging to the statin class of hypolipidemic medications, is a potent inhibitor of HMG-CoA reductase activity with potential anti-hyperlipidemic effects. It inhibits HMG-CoA reductase with an IC50 of 8 nM in a cell-free assay. Fluvastatin is used to reduce plasma cholesterol levels and prevent cardiovascular disease. It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class.
ln Vitro |
The enzyme hydroxymethylglutaryl-coenzyme A reductase (HMGCR), which catalyzes the rate-limiting conversion of HMG-CoA to mevalonic acid in cholesterol biosynthesis, is competitively inhibited by fluvastatin sodium (XU 62320). Studies on HCC (human hepatocellular cancer cells) show that fluvastatin causes G2/M phase arrest. HCC cells display less Bcl-2 and procaspase-9 and more Bax, cleaved caspase-3, and cytochrome c when fluvastatin (XU 62320) is present. The antilipemic drug fluvastatin (XU 62320) lowers plasma cholesterol levels and prevents cardiovascular disease.
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
[1]. Makabe S, et al. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway. Atherosclerosis. 2010 Dec;213(2):377-84.
[2]. Wu Zhang, et al. Fluvastatin, a lipophilic statin, induces apoptosis in human hepatocellular carcinoma cells through mitochondria-operated pathway. Indian J Exp Biol. 2010 Dec;48(12):1167-74. |
Molecular Formula |
C24H25FNNAO4
|
|
---|---|---|
Molecular Weight |
433.45
|
|
CAS # |
93957-55-2
|
|
Related CAS # |
Fluvastatin;93957-54-1;Fluvastatin-d6 sodium;(3S,5R)-Fluvastatin-d6 sodium;2249799-35-5;(3S,5R)-Fluvastatin sodium;94061-81-1
|
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
|
SMILES |
[Na+].FC1C([H])=C([H])C(=C([H])C=1[H])C1C2=C([H])C([H])=C([H])C([H])=C2N(C=1/C(/[H])=C(\[H])/[C@]([H])(C([H])([H])[C@]([H])(C([H])([H])C(=O)[O-])O[H])O[H])C([H])(C([H])([H])[H])C([H])([H])[H]
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 30% propylene glycol, 5% Tween 80, 65% D5W:30 mg/mL |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3071 mL | 11.5354 mL | 23.0707 mL | |
5 mM | 0.4614 mL | 2.3071 mL | 4.6141 mL | |
10 mM | 0.2307 mL | 1.1535 mL | 2.3071 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01551173 | Completed Has Results | Drug: Fluvastatin sodium | Lipid Metabolism Disorders | Novartis Pharmaceuticals | January 2012 | Phase 4 |
NCT03189511 | Completed | Drug: Fluvastatin | Adipose Tissue, Brown Insulin Resistance |
University of Zurich | May 31, 2017 | Phase 4 |
NCT00674297 | Completed Has Results | Drug: Fluvastatin | Antiphospholipid Syndrome | Hospital for Special Surgery, New York | May 2008 | Phase 2 |
NCT00664742 | Completed Has Results | Drug: Fluvastatin XL® | Metabolic Syndrome | Novartis | September 2006 | Phase 4 |